Safety study of MY006 in healthy people and people with peanut allergy
Part of Immune system & allergy clinical trials.
This early-phase study tests a new investigational medication (MY006) to see if it is safe and how the body processes it. It is given to both healthy volunteers and people with peanut allergy. The goal is to gather safety information before larger trials.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 12 and 55 years old (for peanut-allergic part) or 18 to 55 (for healthy volunteer part).
- Your weight must be between 40 and 100 kg (for peanut-allergic part) or 45 and 100 kg (for healthy volunteer part).
- For peanut-allergic participants: you must have a confirmed peanut allergy with a positive skin prick test, blood test, and a positive oral food challenge to a small amount of peanut.
- You must avoid peanuts and other known allergy-causing foods for the whole study.
- You cannot have frequent or recent severe anaphylaxis to peanut or severe/uncontrolled asthma.
- You must be generally healthy with no major medical conditions that could affect safety or study results.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new medication, LCA-0061, in healthy people with high IgE levels (a sign of allergies). Part B specifically includes those with a peanut allergy. The study aims to see how safe the drug is and how the body processes it.
This study tests a new medication called LP-003 that may help people with peanut allergy tolerate peanuts better. If you qualify, you might receive the drug or a placebo, and researchers will see if it reduces allergic reactions to peanuts.
This study aims to identify markers in the blood that could help predict how severe a peanut allergy reaction might be. If you qualify, your child will undergo a supervised peanut challenge to see how their body responds.
This trial tests a new peanut allergy treatment called ENP-501. It aims to see if the medicine can safely help people with peanut allergy become less sensitive to peanuts.
This trial tests an oral (by mouth) immune treatment for people with confirmed peanut allergy. It aims to see whether your immune system can become less reactive to peanuts over time, while keeping you safe during testing with careful emergency planning.
This trial tests a new immunotherapy called UKK-0018 to treat peanut allergies in adults. The goal is to help your body become less sensitive to peanuts over time.
Hear when a new Peanut Allergies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.